---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-034741"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:21:26.751362+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viking reports positive Phase 2b NASH data, $393M cash; net loss $19.2M

## Summary
- VK2809 Phase 2b VOYAGE hit primary endpoint: median liver fat reduction 38-55%; up to 85% of patients achieved ≥30% reduction.
- VK2809 showed significant reductions in LDL-C and triglycerides; Phase 2b 52-week biopsy results expected 1H24.
- Phase 2 study of obesity candidate VK2735 to start 3Q23; Phase 1 oral formulation data expected 4Q23.
- Net loss $19.2M ($0.19 loss/share) vs $17.4M ($0.23) in Q2 2022; R&D spend $13.9M, G&A $9.8M.
- Ended Q2 with $393M cash, boosted by $288M stock offering; cash runway through multiple catalysts.

## SEC filing metadata
- accession: 0000950170-23-034741
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017023034741/0000950170-23-034741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017023034741/vktx-20230726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-034741
- JSON: https://secwatch.observer/filing/0000950170-23-034741.json
- Plain text: https://secwatch.observer/filing/0000950170-23-034741.txt

## Key facts
- Earnings Releases
  Viking Therapeutics, Inc. reported financial results for second quarter and six months ended June 30, 2023.
  - Period: second quarter and six months ended June 30, 2023
  - Result: reported results
  source text: On July 26, 2023, we issued a press release reporting our financial results for the second quarter and six months ended June 30, 2023 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017023034741/0000950170-23-034741-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.